Journal of Clinical Oncology
Articles in this Issue
LuCarbo: A phase 1a/1b trial of <sup>177</sup> Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer.
TPS304 Background: LuPSMA is a proven life-prolonging therapy in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously receiv...
Missed opportunity: PROMs as primary endpoints in bladder cancer trials.
682 Background: Bladder cancer is the sixth most common malignancy in the United States. Recent advances in treatment paradigm have changed the landscape...
Clinical protocols to monitor efficacy of [ <sup>177</sup> Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
39 Background: To assess the prognostic value of post-therapy [ 177 Lu]Lu-PSMA (LuPSMA)-SPECT/CT by visual RECIP 1.0 during LuPSMA...
ABCA1 and ABCG1 cholesterol transporters expression on metastatic renal cell carcinoma: Impact on immunotherapy outcomes (CHOMET study).
568 Background: Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, most patients do not achieve benefits, emphasizing the...
Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study.
511 Background: Local therapy for managing metastatic sites may be a beneficial frontline approach for patients with mRCC. However, existing data are limi...
Somatic genomic landscape of prostate adenocarcinoma at a comprehensive cancer center in New Mexico: A retrospective study (2015-2022).
200 Background: Prostate cancer is the second leading cause of cancer-related deaths in men. In New Mexico, it is the leading cause of cancer death among...
Artificial intelligence–derived tumor volume from baseline MRI and postprostatectomy outcomes following neoadjuvant hormonal therapy for patients with high-risk prostate cancer.
330 Background: Neoadjuvant hormonal therapy (NHT) with androgen deprivation therapy and androgen receptor pathway inhibitor (ARPI) before radical prostat...
Burden of cancer in metastatic renal cell carcinoma (mRCC).
467 Background: Combination regimens and sequencing of multiple agents have significantly improved clinical outcomes for patients (pts.) with mRCC. We sou...
Association between baseline and changes in hemoglobin levels and treatment response and prognosis in metastatic renal cell carcinoma: A Mexican retrospective study.
518 Background: Clinical markers of response and outcome in metastatic renal cell carcinoma (mRCC) are lacking. Low hemoglobin (Hb) is associated with poo...
Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
479 Background: Cabozantinib is approved as a subsequent therapy for patients with metastatic renal cell carcinoma (mRCC) based on the METEOR trial. Howev...
Utility of post-treatment SPECT/CT for identifying disease progression in patients with mCRPC treated with <sup>177</sup> Lu-PSMA-617.
114 Background: Oncologists have traditionally relied upon serial assessments of PSA and periodic imaging (i.e., every 2 to 3 cycles) to monitor treatment...
Racial and ethnic disparities in urinary continence recovery post-prostatectomy.
376 Background: Urinary incontinence is a common complication following prostatectomy, with continence recovery rates varying widely across the literature...
Impact of belzutifan on anemia and hypoxia in sporadic and <i>VHL</i> -syndrome-associated renal cell carcinoma.
522 Background: Inactivation of the tumor suppressor von Hippel-Lindau ( VHL ) gene is associated with...
Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study.
142 Background: Darolutamide, enzalutamide or apalutamide have demonstrated to prolong overall survival in patients with non-metastatic castration-resista...
Exploring social vulnerability in prostate cancer management: Insights into utilization of watchful waiting and active surveillance from 1998 to 2017.
322 Background: Active surveillance (AS) and watchful waiting (WW) represent different conservative management strategies for prostate cancer (PCa), with...
Cabozantinib as subsequent therapy to an immune checkpoint-based therapy in renal cell carcinoma, phase 2 interventional study (AT ASIA, KCSG GU21-02).
547 Background: Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of advanced renal cell carcinoma (aRCC). However, many patie...
S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.
358 Background: Recently, α2,3-sialylated prostate-specific antigen (S2,3PSA)% has been developed as a new serum biomarker for Prostate cancer (PCa). So,...
Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.
538 Background: At first interim analysis of the randomized, multicenter, open-label, phase 3 LITESPARK-005 study (NCT04195750), belzutifan was associated...
Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.
143 Background: In ARASENS, darolutamide (DARO) + ADT + docetaxel (DOC) significantly reduced the risk of death by 32.5% (HR 0.68; 95% CI 0.57–0.80;...
Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC).
837 Background: Disitamab vedotin (DV) combined with toripalimab has shown promising efficacy as neoadjuvant therapy for MIBC, with a pathological CR (pCR...
Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.
101 Background: Treatment landscapes have changed dramatically in prostate cancer in the past decade. Therapies like androgen receptor pathways inhibitors...
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).
786 Background: The “bladder-sparing” trimodal therapy (TMT) has gained popularity among selected patients with muscle-invasive bladder cancer (MIBC) who...
Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.
TPS301 Background: Androgen receptor (AR) somatic mutation activation is a resistance mechanism to AR-directed therapies (ADT) in mCRPC. Upstream targetin...
PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).
107 Background: Patients (pts) with mCRPC can have different metastatic sites with variable outcomes. Lu177-PVT is a novel treatment for mCRPC but respons...
A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).
218 Background: Bipolar androgen therapy (BAT) is a safe and well-tolerated treatment paradigm in metastatic castrate resistant prostate cancer (mCRPC) bu...